Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals. The change is reflective of the company`s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.The official website is now alivus.com. Powered by Capital Market - Live News

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live News

Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ended September 2024 as against Rs 118.74 crore during the previous quarter ended September 2023. Sales declined 14.86% to Rs 506.88 crore in the quarter ended September 2024 as against Rs 595.36 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales506.88595.36 -15 OPM %26.5128.07 - PBDT142.55172.06 -17 PBT127.46158.93 -20 NP95.32118.74 -20 Powered by Capital Market - Live News

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live News

Glenmark Life Sciences announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live News